Electromed, INC Form 4 insider transactions

Electromed's Chief Financial Officer, Bradley M. Nagel, reported a disposition of 674 shares of common stock on June 30, 2026, due to tax withholding obligations.

CEO and President James L. Cunniff exercised 9,700 stock options and subsequently sold a portion of the resulting shares.

Electromed, Inc. CFO Bradley M. Nagel exercised stock options and sold a total of 11,801 shares of common stock.

Electromed, Inc. Director Kathleen Skarvan reported transactions involving the sale of common stock and the acquisition of employee stock options.

Electromed, Inc. Director Kathleen A. Tune was granted 3,000 shares of common stock as restricted stock, scheduled to vest on June 1, 2026.

Electromed, Inc. Director Stan K. Erickson was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Electromed, Inc. Director Gregory Fluet was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Electromed, Inc. Director Joseph L. Galatowitsch was granted 3,000 shares of restricted common stock, vesting on June 1, 2026.

Electromed, Inc. Director Kathleen Skarvan acquired 3,000 shares of common stock, which are restricted and vest in June 2026.

Electromed, Inc. Director Andrea M. Walsh was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Electromed Director Andrew Summers acquired 3,000 shares of common stock as restricted stock, scheduled to vest in June 2026, bringing his direct beneficial ownership to 12,000 shares.

Electromed Director Andrew Summers sold a total of 65,654 shares of common stock across two days in September 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Electromed, Inc. CEO and President James L. Cunniff was granted 17,000 restricted stock units and 31,100 stock options, while also forfeiting shares for tax obligations.

Electromed's Chief Financial Officer, Bradley M. Nagel, reported an increase in his beneficial ownership through new restricted stock and stock option awards, alongside a tax-related share forfeiture.

Director Andrew Summers reports selling shares of Electromed, Inc. (ELMD) in a series of transactions between February 20 and February 24, 2025.

Director Kathleen Skarvan exercised stock options and sold shares of Electromed, Inc. for portfolio diversification and financial planning purposes.

Electromed CEO James L. Cunniff exercised performance stock units (PSUs) and sold shares to cover tax obligations on December 31, 2024.

Director Andrew Summers sold a significant number of Electromed, Inc. shares through multiple transactions on December 5, 2024, via Summers Value Fund LP and SVP Deal Fund I LP.

Director Andrew Summers of Electromed, Inc. sold a significant number of shares across multiple transactions between December 2nd and December 4th, 2024.

Electromed director Andrea M. Walsh acquired 3,000 shares of common stock and disposed of 15,000 shares on December 1, 2024.

Director Kathleen A. Tune acquired 3,000 shares of Electromed, Inc. restricted stock on December 1, 2024, which are scheduled to vest on June 1, 2025.

Electromed director Joseph L. Galatowitsch acquired 3,000 shares of restricted stock on December 1, 2024, scheduled to vest on June 1, 2025.

Director Gregory Fluet acquired 3,000 shares of Electromed, Inc. restricted stock on December 1, 2024, scheduled to vest on June 1, 2025.

Director Stan K. Erickson of Electromed, Inc. reports acquiring 3,000 shares of common stock and a decrease of 1,500 shares held indirectly.

Electromed director Kathleen Skarvan acquired 3,000 shares of common stock through a stock award, while also reporting indirect ownership of 28,989 shares held in trust.

Director Andrew Summers of Electromed, Inc. acquired 3,000 shares of restricted stock on December 1, 2024, according to a recent SEC filing.

Electromed director Kathleen Skarvan sold a total of 149,999 shares of common stock across multiple transactions on November 18th and 19th, 2024, as part of a portfolio diversification strategy.

Electromed's CEO, James L. Cunniff, reports the vesting of performance stock units (PSUs) and subsequent stock transactions, including shares withheld for tax obligations.

Electromed's Chief Financial Officer, Bradley M. Nagel, reported acquiring 5,500 shares of common stock and 12,200 employee stock options on September 3, 2024.

Electromed's CEO, James L. Cunniff, reports acquisition of common stock and stock options, with vesting schedules extending to 2027.